The California-based company, PhageTech, is developing a groundbreaking platform that utilizes bio conducting materials to create a new generation of sensors. These sensors have the ability to accurately detect diseases like cancer and infectious diseases in their earliest stages, providing immediate and convenient results at a low cost. Unlike traditional antibody-based assays, PhageTech's sensors are highly sensitive and selective, allowing for the detection of multiple disease biomarkers simultaneously. This disruptive technology has the potential to transform the field of diagnostics, replacing expensive and complicated methods with a more accessible and robust solution. With nine patents pending or issued, PhageTech's innovative approach promises rapid and accurate diagnostic screening at a fraction of the current costs, potentially impacting the diagnosis and treatment of various diseases worldwide.